Eric E Swayze

List of Publications by Year
in descending order

160 papers	11,207 citations	31976 53 h-index	33894 99 g-index
179 all docs	179 docs citations	179 times ranked	9874 citing authors

#	Article	IF	Citations
1	Evaluation of Phosphorus and Non-Phosphorus Neutral Oligonucleotide Backbones for Enhancing Therapeutic Index of Gapmer Antisense Oligonucleotides. Nucleic Acid Therapeutics, 2022, 32, 40-50.	3.6	10
2	Backbone Hydrocarbon-Constrained Nucleic Acids Modulate Hybridization Kinetics for RNA. Journal of the American Chemical Society, 2022, 144, 1941-1950.	13.7	5
3	Site-specific incorporation of 5â€²-methyl DNA enhances the therapeutic profile of gapmer ASOs. Nucleic Acids Research, 2021, 49, 1828-1839.	14.5	26
4	Î±-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinsonâ€™s disease. JCI Insight, 2021, 6, .	5.0	60
5	Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides. Nucleic Acids Research, 2021, 49, 9026-9041.	14.5	61
6	The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration. Nucleic Acids Research, 2021, 49, 657-673.	14.5	58
7	Targeted Delivery of Antisense Oligonucleotides Using Neurotensin Peptides. Journal of Medicinal Chemistry, 2020, 63, 8471-8484.	6.4	27
8	Convective forces increase rostral delivery of intrathecal radiotracers and antisense oligonucleotides in the cynomolgus monkey nervous system. Journal of Translational Medicine, 2020, 18, 309.	4.4	20
9	Mechanisms of palmitic acid-conjugated antisense oligonucleotide distribution in mice. Nucleic Acids Research, 2020, 48, 4382-4395.	14.5	33
10	Likelihood of Nonspecific Activity of Gapmer Antisense Oligonucleotides Is Associated with Relative Hybridization Free Energy. Nucleic Acid Therapeutics, 2020, 30, 215-228.	3.6	22
11	An Antisense Oligonucleotide Leads to Suppressed Transcription of Hdac2 and Long-Term Memory Enhancement. Molecular Therapy - Nucleic Acids, 2020, 19, 1399-1412.	5.1	18
12	Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides. Nucleic Acids Research, 2020, 48, 1691-1700.	14.5	63
13	Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle. Nucleic Acids Research, 2019, 47, 6029-6044.	14.5	93
14	Site-specific replacement of phosphorothioate with alkyl phosphonate linkages enhances the therapeutic profile of gapmer ASOs by modulating interactions with cellular proteins. Nucleic Acids Research, 2019, 47, 5465-5479.	14.5	77
15	Characterization of the interactions of chemically-modified therapeutic nucleic acids with plasma proteins using a fluorescence polarization assay. Nucleic Acids Research, 2019, 47, 1110-1122.	14.5	104
16	Conjugation of hydrophobic moieties enhances potency of antisense oligonucleotides in the muscle of rodents and non-human primates. Nucleic Acids Research, 2019, 47, 6045-6058.	14.5	48
17	Targeting Huntingtin Expression in Patients with Huntingtonâ€™s Disease. New England Journal of Medicine, 2019, 380, 2307-2316.	27.0	493
18	A modular analysis of microglia gene expression, insights into the aged phenotype. BMC Genomics, 2019, 20, 164.	2.8	24

#	Article	IF	Citations
19	S-Acyl-2-Thioethyl: A Convenient Base-Labile Protecting Group for the Synthesis of siRNAs Containing 5â€²-Vinylphosphonate. Molecules, 2019, 24, 225.	3.8	0
20	The Medicinal Chemistry of RNase H-activating Antisense Oligonucleotides. RSC Drug Discovery Series, 2019, , 32-61.	0.3	8
21	Brain pharmacology of intrathecal antisense oligonucleotides revealed through multimodal imaging. JCI Insight, 2019, 4, .	5.0	60
22	Antisense oligonucleotides extend survival of prion-infected mice. JCI Insight, 2019, 4, .	5.0	80
23	Receptor-Mediated Uptake of Phosphorothioate Antisense Oligonucleotides in Different Cell Types of the Liver. Nucleic Acid Therapeutics, 2018, 28, 119-127.	3.6	49
24	Antisense oligonucleotides selectively suppress target RNA in nociceptive neurons of the pain system and can ameliorate mechanical pain. Pain, 2018, 159, 139-149.	4.2	26
25	Huntingtin suppression restores cognitive function in a mouse model of Huntingtonâ€™s disease. Science Translational Medicine, 2018, 10, .	12.4	89
26	Evaluation of the effect of 2â€²-O-methyl, fluoro hexitol, bicyclo and Morpholino nucleic acid modifications on potency of GalNAc conjugated antisense oligonucleotides in mice. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3774-3779.	2.2	16
27	Antisense oligonucleotides targeting mutant Ataxin-7 restore visual function in a mouse model of spinocerebellar ataxia type 7. Science Translational Medicine, 2018, 10, .	12.4	63
28	Antisense oligonucleotideâ€“mediated ataxin-1 reduction prolongs survival in SCA1 mice and reveals disease-associated transcriptome profiles. JCI Insight, 2018, 3, .	5.0	106
29	Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. Journal of Clinical Investigation, 2018, 128, 3558-3567.	8.2	171
30	Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Science Translational Medicine, 2017, 9, .	12.4	354
31	Co-Administration of an Excipient Oligonucleotide Helps Delineate Pathways of Productive and Nonproductive Uptake of Phosphorothioate Antisense Oligonucleotides in the Liver. Nucleic Acid Therapeutics, 2017, 27, 209-220.	3.6	23
32	Fluorinated Nucleotide Modifications Modulate Allele Selectivity of SNP-Targeting Antisense Oligonucleotides. Molecular Therapy - Nucleic Acids, 2017, 7, 20-30.	5.1	24
33	LRRK2 Antisense Oligonucleotides Ameliorate Î±-Synuclein Inclusion Formation in a Parkinsonâ€™s Disease Mouse Model. Molecular Therapy - Nucleic Acids, 2017, 8, 508-519.	5.1	167
34	A novel humanized mouse model of Huntington disease for preclinical development of therapeutics targeting mutant huntingtin alleles. Human Molecular Genetics, 2017, 26, ddx021.	2.9	37
35	Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor. Nucleic Acids Research, 2017, 45, 2294-2306.	14.5	72
36	PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models. Journal of Clinical Investigation, 2017, 128, 359-368.	8.2	117

#	Article	IF	Citations
37	A convenient synthesis of 5â€²-triantennary N-acetyl-galactosamine clusters based on nitromethanetrispropionic acid. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2194-2197.	2.2	9
38	Elucidation of the Biotransformation Pathways of a Galnac3-conjugated Antisense Oligonucleotide in Rats and Monkeys. Molecular Therapy - Nucleic Acids, 2016, 5, e319.	5.1	46
39	Synergistic effect of phosphorothioate, 5â€²-vinylphosphonate and GalNAc modifications for enhancing activity of synthetic siRNA. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2817-2820.	2.2	44
40	Pharmacokinetic and Pharmacodynamic Investigations of ION-353382, a Model Antisense Oligonucleotide: Using Alpha-2-Macroglobulin and Murinoglobulin Double-Knockout Mice. Nucleic Acid Therapeutics, 2016, 26, 223-235.	3.6	34
41	Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice. Molecular Therapy - Nucleic Acids, 2016, 5, e317.	5.1	74
42	Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys. Nucleic Acid Therapeutics, 2016, 26, 372-380.	3.6	57
43	Tcf4 Regulates Synaptic Plasticity, DNA Methylation, and Memory Function. Cell Reports, 2016, 16, 2666-2685.	6.4	113
44	Conjugation of mono and di-GalNAc sugars enhances the potency of antisense oligonucleotides via ASGR mediated delivery to hepatocytes. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3690-3693.	2.2	36
45	Design, synthesis, and duplex-stabilizing properties of conformationally constrained tricyclic analogues of LNA. Organic and Biomolecular Chemistry, 2016, 14, 2034-2040.	2.8	14
46	Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts. Nucleic Acids Research, 2016, 44, 2093-2109.	14.5	142
47	Comprehensive Structureâ€“Activity Relationship of Triantennary N-Acetylgalactosamine Conjugated Antisense Oligonucleotides for Targeted Delivery to Hepatocytes. Journal of Medicinal Chemistry, 2016, 59, 2718-2733.	6.4	107
48	Efficient Synthesis and Biological Evaluation of 5â€²-GalNAc Conjugated Antisense Oligonucleotides. Bioconjugate Chemistry, 2015, 26, 1451-1455.	3.6	68
49	Identification of metabolically stable 5â€²-phosphate analogs that support single-stranded siRNA activity. Nucleic Acids Research, 2015, 43, 2993-3011.	14.5	67
50	Identification and Characterization of Modified Antisense Oligonucleotides Targeting DMPK in Mice and Nonhuman Primates for the Treatment of Myotonic Dystrophy Type 1. Journal of Pharmacology and Experimental Therapeutics, 2015, 355, 329-340.	2.5	106
51	Solid-phase synthesis of 5â€²-triantennary N-acetylgalactosamine conjugated antisense oligonucleotides using phosphoramidite chemistry. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4127-4130.	2.2	21
52	Synthetic CRISPR RNA-Cas9â€“guided genome editing in human cells. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E7110-7.	7.1	151
53	Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Research, 2014, 42, 8796-8807.	14.5	465
54	Exploring the Effect of Sequence Length and Composition on Allele-Selective Inhibition of Human Huntingtin Expression by Single-Stranded Silencing RNAs. Nucleic Acid Therapeutics, 2014, 24, 199-209.	3.6	21

#	Article	IF	Citations
55	Synthesis and Duplexâ€Stabilizing Properties of Fluorinated Nâ€Methanocarbathymidine Analogues Locked in the C3â€²â€endo Conformation. Angewandte Chemie - International Edition, 2014, 53, 9893-9897.	13.8	23
56	In Vivo Evaluation of Candidate Allele-specific Mutant Huntingtin Gene Silencing Antisense Oligonucleotides. Molecular Therapy, 2014, 22, 2093-2106.	8.2	115
57	Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages. Nucleic Acids Research, 2014, 42, 13456-13468.	14.5	98
58	Comparison of Duplex Stabilizing Properties of 2â€²-Fluorinated Nucleic Acid Analogues with Furanose and Non-Furanose Sugar Rings. Journal of Organic Chemistry, 2014, 79, 8877-8881.	3.2	22
59	Differential Effects on Allele Selective Silencing of Mutant Huntingtin by Two Stereoisomers of Î±,Î²-Constrained Nucleic Acid. ACS Chemical Biology, 2014, 9, 1975-1979.	3.4	13
60	Synthesis and Antisense Properties of 2â€²â€Oâ€(2Sâ€Methoxypropyl)â€RNAâ€Modified Gapmer Antisense Oligonucleotides. ChemMedChem, 2014, 9, 2040-2044.	3.2	3
61	Allele-Selective Inhibition of Mutant Atrophin-1 Expression by Duplex and Single-Stranded RNAs. Biochemistry, 2014, 53, 4510-4518.	2.5	31
62	Allele-Specific Suppression of Mutant Huntingtin Using Antisense Oligonucleotides: Providing a Therapeutic Option for All Huntington Disease Patients. PLoS ONE, 2014, 9, e107434.	2.5	92
63	Synthesis and Biophysical Properties of Constrained d-Altritol Nucleic Acids (cANA). Organic Letters, 2013, 15, 4316-4319.	4.6	18
64	A Constrained Tricyclic Nucleic Acid Analogue of Î±-<scp>l</scp>-LNA: Investigating the Effects of Dual Conformational Restriction on Duplex Thermal Stability. Journal of Organic Chemistry, 2013, 78, 9064-9075.	3.2	19
65	Synthesis of cis- and trans-Î±-l-[4.3.0]Bicyclo-DNA Monomers for Antisense Technology: Methods for the Diastereoselective Formation of Bicyclic Nucleosides. Journal of Organic Chemistry, 2013, 78, 9051-9063.	3.2	11
66	Lipid Nanoparticles Improve Activity of Single-Stranded siRNA and Gapmer Antisense Oligonucleotides in Animals. ACS Chemical Biology, 2013, 8, 1402-1406.	3.4	41
67	Synthesis, Duplex Stabilization and Structural Properties of a Fluorinated Carbocyclic LNA Analogue. ChemBioChem, 2013, 14, 58-62.	2.6	19
68	Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. Nucleic Acids Research, 2013, 41, 9634-9650.	14.5	138
69	ss-siRNAs allele selectively inhibit ataxin-3 expression: multiple mechanisms for an alternative gene silencing strategy. Nucleic Acids Research, 2013, 41, 9570-9583.	14.5	41
70	TricycloDNA-modified oligo-2â€²-deoxyribonucleotides reduce scavenger receptor B1 mRNA in hepatic and extra-hepatic tissuesâ€”a comparative study of oligonucleotide length, design and chemistry. Nucleic Acids Research, 2012, 40, 6135-6143.	14.5	86
71	Structure Activity Relationships of Î±-L-LNA Modified Phosphorothioate Gapmer Antisense Oligonucleotides in Animals. Molecular Therapy - Nucleic Acids, 2012, 1, e47.	5.1	38
72	Single-Stranded RNAs Use RNAi to Potently and Allele-Selectively Inhibit Mutant Huntingtin Expression. Cell, 2012, 150, 895-908.	28.9	250

#	Article	IF	Citations
73	Single-Stranded siRNAs Activate RNAi in Animals. Cell, 2012, 150, 883-894.	28.9	239
74	Structure and nuclease resistance of 2â€²,4â€²-constrained 2â€²-O-methoxyethyl (cMOE) and 2â€²-O-ethyl (cEt) modified DNAs. Chemical Communications, 2012, 48, 8195.	4.1	66
75	Insights from Crystal Structures into the Opposite Effects on RNA Affinity Caused by the S- and R-6â€²-Methyl Backbone Modifications of 3â€²-Fluoro Hexitol Nucleic Acid. Biochemistry, 2012, 51, 7-9.	2.5	15
76	Scalable synthesis of substituted 2,7-dimethyl-9-phenylxanthen-9-ol (DMPx-OH): useful for the preparation of crystalline 5â€²-O-DMPx-protected nucleosides. Tetrahedron Letters, 2012, 53, 4669-4672.	1.4	8
77	Synthesis and Antisense Properties of Fluoro Cyclohexenyl Nucleic Acid (F-CeNA), a Nuclease Stable Mimic of 2â€²-Fluoro RNA. Journal of Organic Chemistry, 2012, 77, 5074-5085.	3.2	41
78	Structureâ€Based Design of a Highly Constrained Nucleic Acid Analogue: Improved Duplex Stabilization by Restricting Sugar Pucker and Torsion Angle Î³. Angewandte Chemie - International Edition, 2012, 51, 11242-11245.	13.8	31
79	Structural requirements for hybridization at the 5â€²-position are different in Î±-l-LNA as compared to Î²-d-LNA. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 296-299.	2.2	18
80	Synthesis, Improved Antisense Activity and Structural Rationale for the Divergent RNA Affinities of 3â€²-Fluoro Hexitol Nucleic Acid (FHNA and Ara-FHNA) Modified Oligonucleotides. Journal of the American Chemical Society, 2011, 133, 16642-16649.	13.7	69
81	Synthesis and biophysical evaluation of 3â€²-Me-Î±-l-LNA â€“ Substitution in the minor groove of Î±-l-LNA duplexes. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 4690-4694.	2.2	11
82	Replacing the 2â€²-oxygen with an exocyclic methylene group reverses the stabilization effects of Î±-l-LNA. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 588-591.	2.2	13
83	Synthesis and biophysical characterization of R-6â€²-Me-Î±-l-LNA modified oligonucleotides. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 1122-1125.	2.2	17
84	Allele-selective inhibition of ataxin-3 (ATX3) expression by antisense oligomers and duplex RNAs. Biological Chemistry, 2011, 392, 315-25.	2.5	49
85	Structure-based design, synthesis and A-site rRNA co-crystal complexes of novel amphiphilic aminoglycoside antibiotics with new binding modes: A synergistic hydrophobic effect against resistant bacteria. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 7097-7101.	2.2	40
86	Inhibitor-induced structural change in the HCV IRES domain IIa RNA. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 7263-7268.	7.1	52
87	Antisense Oligonucleotides Containing Conformationally Constrained 2â€²,4â€²-(N-Methoxy)aminomethylene and 2â€²,4â€²-Aminooxymethylene and 2â€²-O,4â€²-C-Aminomethylene Bridged Nucleoside Analogues Show Improved Potency in Animal Models. Journal of Medicinal Chemistry, 2010, 53, 1636-1650.	6.4	71
88	An Exocyclic Methylene Group Acts As a Bioisostere of the 2â€²-Oxygen Atom in LNA. Journal of the American Chemical Society, 2010, 132, 14942-14950.	13.7	82
89	Synthesis and Biophysical Evaluation of 2â€²,4â€²-Constrained 2â€²O-Methoxyethyl and 2â€²,4â€²-Constrained 2â€²O-Ethyl Nucleic Acid Analogues. Journal of Organic Chemistry, 2010, 75, 1569-1581.	3.2	182
90	Configuration of the 5â€²-Methyl Group Modulates the Biophysical and Biological Properties of Locked Nucleic Acid (LNA) Oligonucleotides. Journal of Medicinal Chemistry, 2010, 53, 8309-8318.	6.4	32

#	Article	IF	Citations
91	Allele-Selective Inhibition of Mutant Huntingtin Expression with Antisense Oligonucleotides Targeting the Expanded CAG Repeat. Biochemistry, 2010, 49, 10166-10178.	2.5	127
92	RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform. Annual Review of Pharmacology and Toxicology, 2010, 50, 259-293.	9.4	1,136
93	Peptide Nucleic Acids Conjugated to Short Basic Peptides Show Improved Pharmacokinetics and Antisense Activity in Adipose Tissue. Journal of Medicinal Chemistry, 2010, 53, 3919-3926.	6.4	30
94	Potent inhibition of microRNA in vivo without degradation. Nucleic Acids Research, 2009, 37, 70-77.	14.5	189
95	Activity of siRNAs with 2-Thio-2â€²-O-Methyluridine Modification in Mammalian Cells. Nucleosides, Nucleotides and Nucleic Acids, 2009, 28, 902-910.	1.1	5
96	Short Antisense Oligonucleotides with Novel 2â€²â^'4â€² Conformationaly Restricted Nucleoside Analogues Show Improved Potency without Increased Toxicity in Animals. Journal of Medicinal Chemistry, 2009, 52, 10-13.	6.4	236
97	Design, Synthesis And Evaluation Of Constrained Methoxyethyl (cMOE) and Constrained Ethyl (cEt) Nucleoside Analogs. Nucleic Acids Symposium Series, 2008, 52, 553-554.	0.3	77
98	Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Research, 2007, 35, 687-700.	14.5	361
99	The Positional Influence of the Helical Geometry of the Heteroduplex Substrate on Human RNase H1 Catalysis. Molecular Pharmacology, 2007, 71, 73-82.	2.3	35
100	Structure-Based Design, Synthesis, and A-Site rRNA Cocrystal Complexes of Functionally Novel Aminoglycoside Antibiotics:Â C2â€˜Ââ€˜ Ether Analogues of Paromomycin. Journal of Medicinal Chemistry, 2007, 50, 2352-2369.	6.4	54
101	Probing the ribosomal RNA A-site with functionally diverse analogues of paromomycinâ€”synthesis of ring I mimetics. Tetrahedron, 2007, 63, 827-846.	1.9	7
102	Trisaccharide mimetics of the aminoglycoside antibiotic neomycin. Organic and Biomolecular Chemistry, 2006, 4, 1328.	2.8	12
103	Evaluation of Basic Amphipathic Peptides for Cellular Delivery of Antisense Peptide Nucleic Acids. Journal of Medicinal Chemistry, 2006, 49, 2534-2542.	6.4	26
104	Improving RNA Interference in Mammalian Cells by 4â€˜-Thio-Modified Small Interfering RNA (siRNA):Â Effect on siRNA Activity and Nuclease Stability When Used in Combination with 2â€˜-O-Alkyl Modifications. Journal of Medicinal Chemistry, 2006, 49, 1624-1634.	6.4	113
105	RNA interference by 2â€²,5â€²-linked nucleic acid duplexes in mammalian cells. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 3238-3240.	2.2	26
106	Competition for RISC binding predicts in vitro potency of siRNA. Nucleic Acids Research, 2006, 34, 4467-4476.	14.5	108
107	SAR by MS:â€‰ Discovery of a New Class of RNA-Binding Small Molecules for the Hepatitis C Virus:â€‰ Internal Ribosome Entry Site IIA Subdomain. Journal of Medicinal Chemistry, 2005, 48, 7099-7102.	6.4	149
108	The synthesis and 16S A-site rRNA recognition of carbohydrate-free aminoglycosides. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 4919-4922.	2.2	12

#	Article	IF	Citations
109	Structureâ"Activity Relationship Study on a Simple Cationic Peptide Motif for Cellular Delivery of Antisense Peptide Nucleic Acid. Journal of Medicinal Chemistry, 2005, 48, 6741-6749.	6.4	32
110	Positional Effect of Chemical Modifications on Short Interference RNA Activity in Mammalian Cells. Journal of Medicinal Chemistry, 2005, 48, 4247-4253.	6.4	259
111	An Efficient Synthesis of Gougerotin and Related Analogues Using Solid- and Solution-Phase Methodology. Organic Letters, 2005, 7, 3429-3432.	4.6	17
112	Fully 2â€˜-Modified Oligonucleotide Duplexes with Improved in Vitro Potency and Stability Compared to Unmodified Small Interfering RNA. Journal of Medicinal Chemistry, 2005, 48, 901-904.	6.4	416
113	Synthesis and biological evaluations of novel benzimidazoles as potential antibacterial agents. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 1217-1220.	2.2	79
114	Antibacterial Aminoglycosides with a Modified Mode of Binding to the Ribosomal-RNA Decoding Site. Angewandte Chemie - International Edition, 2004, 43, 6735-6738.	13.8	88
115	Disaccharide Mimetics of the Aminoglycoside Antibiotic Neamine. ChemBioChem, 2004, 5, 1228-1236.	2.6	23
116	Synthesis and Biological Evaluations of Novel Benzimidazoles as Potential Antibacterial Agents.. ChemInform, 2004, 35, no.	0.0	0
117	Synthesis and evaluation of novel bacterial rRNA-binding benzimidazoles by mass spectrometry. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 695-699.	2.2	34
118	Optimizing the antibacterial activity of a lead structure discovered by â€˜SAR by MSâ€™ technology. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 5257-5261.	2.2	12
119	Aryl urea analogs with broad-spectrum antibacterial activity. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 5569-5572.	2.2	36
120	Biaryl guanidine inhibitors of in vitro HCV-IRES activity. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 5139-5143.	2.2	29
121	Synthesis of 2â€²â€Substituted MMI Linked Nucleosidic Dimers: An Optimization Study in Search of High Affinity Oligonucleotides for Use in Antisense Constructs. Nucleosides, Nucleotides and Nucleic Acids, 2004, 23, 411-438.	1.1	7
122	Synthesis and Biological Activity of 5â€Fluorotubercidin. Nucleosides, Nucleotides and Nucleic Acids, 2004, 23, 161-170.	1.1	33
123	Synthesis of linked carbohydrates and evaluation of Their binding for 16S RNA by mass spectrometry. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 3915-3918.	2.2	16
124	Title is missing!. Angewandte Chemie, 2003, 115, 3531-3534.	2.0	4
125	Antibacterial Activity of Quinoloneâ€"Macrocycle Conjugates.. ChemInform, 2003, 34, no.	0.0	0
126	2-Piperidin-4-yl-benzimidazoles with Broad Spectrum Antibacterial Activities.. ChemInform, 2003, 34, no.	0.0	0

#	Article	IF	Citations
127	Design and Synthesis of Paromomycin-Related Heterocycle-Substituted Aminoglycoside Mimetics Based on a Mass Spectrometry RNA-Binding Assay. Angewandte Chemie - International Edition, 2003, 42, 3409-3412.	13.8	41
128	Tobramycin analogues with C-5 aminoalkyl ether chains intended to mimic rings III and IV of paromomycin. Tetrahedron, 2003, 59, 983-993.	1.9	47
129	Probing the functional requirements of the l-haba side-chain of amikacinâ€"synthesis, 16S A-site rRNA binding, and antibacterial activity. Tetrahedron, 2003, 59, 995-1007.	1.9	27
130	2-Piperidin-4-yl-benzimidazoles with broad spectrum antibacterial activities. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 3253-3256.	2.2	78
131	Antibacterial activity of quinoloneâ€"Macrocycle conjugates. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 1635-1638.	2.2	26
132	Efficient Synthesis of Heterocyclic 2-Deoxysteptamine Derivatives as RNA Binding Ligands. Chemistry Letters, 2003, 32, 908-909.	1.3	8
133	New Inhibitors of Bacterial Protein Synthesis from a Combinatorial Library of Macrocycles. Journal of Medicinal Chemistry, 2002, 45, 3430-3439.	6.4	32
134	SAR by MS:Â A Ligand Based Technique for Drug Lead Discovery Against Structured RNA Targets. Journal of Medicinal Chemistry, 2002, 45, 3816-3819.	6.4	148
135	RNA-targeted therapeutics: prospects and promise. Expert Opinion on Therapeutic Patents, 2002, 12, 1367-1374.	5.0	5
136	Reexamination of Neomycin B Degradation:â€‰ Efficient Preparation of Its CD and D Rings as Protected Glycosyl Donors. Organic Letters, 2002, 4, 3455-3458.	4.6	29
137	Efficient solution phase synthesis of 2-(N-acyl)-aminobenzimidazoles. Tetrahedron Letters, 2002, 43, 7303-7306.	1.4	27
138	An Efficient Synthesis of Mimetics of Neamine for RNA Recognition. Organic Letters, 2001, 3, 1621-1623.	4.6	41
139	Automated solid-phase synthesis of linear nitrogen-linked compounds. , 2000, 71, 19-27.		5
140	Efficient synthesis of neomycin B related aminoglycosides. Tetrahedron Letters, 2000, 41, 4049-4052.	1.4	28
141	Solid-Phase Synthesis of a Heterocyclic Ethylenediamine-Derivatized Library. ACS Combinatorial Science, 2000, 2, 441-444.	3.3	6
142	Characterization of Low-Affinity Complexes between RNA and Small Molecules Using Electrospray Ionization Mass Spectrometryâ€. Journal of the American Chemical Society, 2000, 122, 9933-9938.	13.7	83
143	A Solid-Phase Synthesis of N,Nâ€˜-Disubstituted Ureas and Perhydroimidazo[1,5-a]pyrazines via the Curtius Rearrangement. Organic Letters, 2000, 2, 3309-3311.	4.6	30
144	Î²-Amino acid facilitates macrocyclic ring closure in a combinatorial library. Tetrahedron Letters, 1999, 40, 7757-7760.	1.4	32

#	Article	IF	Citations
145	Solid-phase synthesis of a library of functionalized aminodiol scaffolds. , 1999, 61, 143-154.		14
146	An Improved Large-Scale Preparation of Benzimidazole-2-Sulfonic Acids and 2-Chlorobenzimidazoles.â€¡. Synthetic Communications, 1998, 28, 1703-1712.	2.1	15
147	Two-dimensional parallel array technology as a new approach to automated combinatorial solid-phase organic synthesis. , 1998, 61, 33-45.		17
148	Synthesis and Evaluation Of 2â€³-Modified MMI Linked Dimers in Antisense Constructs. Nucleosides & Nucleotides, 1997, 16, 959-962.	0.5	6
149	Concept, Discovery and Development of MMI Linkage: Story of a Novel Linkage: for Antisense Constructs. Nucleosides & Nucleotides, 1997, 16, 907-916.	0.5	20
150	The Synthesis of the Sixteen Possible 2â€²-O-Methyl MMI Dimer Phosphoramidites: Building Blocks for the Synthesis of Novel Antisense Oligonucleotides. Nucleosides & Nucleotides, 1997, 16, 971-972.	0.5	4
151	Synthesis, Antiproliferative and Antiviral Activity of Imidazo[4,5-d]isothiazole Nucleosides as 5:5 Fused Analogs of Nebularine and 6-Methylpurine Ribonucleoside. Journal of Medicinal Chemistry, 1997, 40, 771-784.	6.4	22
152	An Efficient Multigram Synthesis of Monomers for the Preparation of Novel Oligonucleotides Containing Isosteric Non-Phosphorous Backbones. Nucleosides & Nucleotides, 1997, 16, 1629-1632.	0.5	6
153	Secondary amide-based linkers for solid phase organic synthesis. Tetrahedron Letters, 1997, 38, 8465-8468.	1.4	67
154	The solid phase synthesis of trisubstituted 1,4-diazabicyclo[4.3.0]nonan-2-one scaffolds: On bead monitoring of heterocycle forming reactions using 15N NMR. Tetrahedron Letters, 1997, 38, 8643-8646.	1.4	34
155	Synthesis of Novel Nucleic Acid Mimicsviathe Stereoselective Intermolecular Radical Coupling of 3â€²-Iodo Nucleosides and Formaldoximes1. Journal of Organic Chemistry, 1996, 61, 8186-8199.	3.2	42
156	The Synthesis of Substituted Imidazo[4,5-d]isothiazoles via the Ring Annulation of Isothiazole Diamines: An Investigation of the Chemical, Physical, and Biological Properties of Several Novel 5:5 Fused Analogs of the Purine Ring System. Journal of Organic Chemistry, 1995, 60, 6309-6317.	3.2	15
157	Synthesis of 1-(2-aminopropyl)benzimidazoles, structurally related to the TIBO derivative R82150, with activity against human immunodeficiency virus. Bioorganic and Medicinal Chemistry Letters, 1993, 3, 543-546.	2.2	19
158	The synthesis of several imidazo[4,5â€d]isothiazoles. Derivatives of a new ring system. Journal of Heterocyclic Chemistry, 1993, 30, 1379-1383.	2.6	4
159	Synthesis, Antiproliferative, and Antiviral Evaluation of Certain Acyclic 6-Substituted Pyrrolo[2,3-D]-pyrimidine Nucleoside Analogs Related to Sangivamycin and Toyocamycin. Nucleosides & Nucleotides, 1992, 11, 1507-1527.	0.5	13
160	Improved synthesis and biological evaluation of an acyclic thiosangivamycin active against human cytomegalovirus. Antiviral Research, 1992, 19, 15-28.	4.1	15